Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Xinmin Zhao,Xianghua Wu,Huijie Wang,Songtao Lai,Jialei Wang

DOI: https://doi.org/10.1002/mco2.237

2023-01-01

MedComm

Abstract:[This corrects the article DOI: 10.1002/mco2.237.].

What problem does this paper attempt to address?

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Jiaojiao Hao,Zhenglin Li,Changlin Zhang,Wendan Yu,Zhipeng Tang,Yixin Li,Xu Feng,Yue Gao,Quentin Liu,Wenlin Huang,Wei Guo,Wuguo Deng

DOI: https://doi.org/10.62347/suki5933

2024-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 13 in vol. 7, PMID: 28123844.].
Correction: ShRNA-Targeted COMMD7 Suppresses Hepatocellular Carcinoma Growth.

Lu Zheng,Ping Liang,Jing Li,Xiao-Bing Huang,Shi-Cheng Liu,Hong-Zhi Zhao,Ke-Qiang Han,Zheng Wang

DOI: https://doi.org/10.1371/journal.pone.0214259

IF: 3.7

2019-01-01

PLoS ONE

Abstract:[This corrects the article DOI: 10.1371/journal.pone.0045412.].
Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Wancun Zhang,Lili Xia,Xiangyu Ren,Mengyuan Cui,Tianguang Liu,Chen Ling,Yanqi Xu,Dawei Deng,Xianwei Zhang,Yueqing Gu,Peng Wang

DOI: https://doi.org/10.1039/d4bm90077d

2024-10-25

Biomaterials Science

Abstract:Correction for 'The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer' by Wancun Zhang et al. , Biomater. Sci. , 2020, 8 , 5941–5954, https://doi.org/10.1039/D0BM01035A.

materials science, biomaterials
Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Yue Zhou,Qing Zhang,Minjia Wang,Chengzhi Huang,Xueqing Yao

DOI: https://doi.org/10.3389/fonc.2022.916983

IF: 4.7

2022-06-27

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2022.827891.].

oncology
Correction To: MiRNA-195-5p Functions As a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Jing Zheng,Tao Xu,Feng Chen,Ying Zhang

DOI: https://doi.org/10.1007/s12253-020-00794-3

2020-01-01

Abstract:The original version of this article unfortunately contained an error in the affiliation section.
Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Qi Chang Zheng,Shuai Jiang,Yu Zhe Wu,Dan Shang,Yong Zhang,Shao Bo Hu,Xiang Cheng,Chen Zhang,Ping Sun,Yang Gao,Zi Fang Song,Min Li

DOI: https://doi.org/10.3389/fbioe.2021.656268

IF: 5.7

2021-02-11

Frontiers in Bioengineering and Biotechnology

Abstract:[This corrects the article DOI: 10.3389/fbioe.2020.00512.].

multidisciplinary sciences
Preparation of AS1411 Aptamer Modified Mn-MoS2 QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma [Corrigendum]

Shaohui Zheng,Min Zhang,Hongyan Bai,Meijuan He,Lina Dong,Lulu Cai,Mingming Zhao,Qi Wang,Kai Xu,Jingjing Li

DOI: https://doi.org/10.2147/ijn.s405918

IF: 7.033

2023-01-01

International Journal of Nanomedicine

Abstract:[This corrects the article DOI: 10.2147/IJN.S215883.].

pharmacology & pharmacy,nanoscience & nanotechnology
Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Lin Wang,Xiang-Bo Ji,Li-Hong Wang,Jian-Ge Qiu,Feng-Mei Zhou,Wen-Jing Liu,Di-di Wan,Marie Chai-mi Lin,Ling-Zhi Liu,Jian-Ying Zhang,Bing-Hua Jiang

DOI: https://doi.org/10.3389/fcell.2022.1008088

IF: 5.5

2022-09-23

Frontiers in Cell and Developmental Biology

Abstract:[This corrects the article DOI: 10.3389/fcell.2020.00840.].

cell biology,developmental biology
Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Xuan Wei,Juanjuan Shi,Qianhan Lin,Xiaoxue Ma,Yingxin Pang,Hongluan Mao,Rui Li,Wei Lu,Yu Wang,Peishu Liu

DOI: https://doi.org/10.3389/fonc.2021.742374

IF: 4.7

2021-09-07

Frontiers in Oncology

Abstract:[This corrects the article DOI: 10.3389/fonc.2021.642229.].

oncology
Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Hang-Ping Yao,Liang Feng,Sreedhar Reddy Suthe,Ling-Hui Chen,Tian-Hao Weng,Chen-Yu Hu,Eun Sung Jun,Zhi-Gang Wu,Wei-Lin Wang,Song Cheol Kim,Xiang-Min Tong,Ming-Hai Wang

DOI: https://doi.org/10.1186/s40425-019-0571-7

IF: 12.469

2019-01-01

Journal for ImmunoTherapy of Cancer

Abstract:Following publication of the original article [1], the author reported two errors in the authors affiliations:
Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Jianbin Xu,Guolin Zhang,Xin Luo,Di Wang,Wei Zhou,Yan Zhang,Wei Zhang,Jiaxin Chen,Qing Meng,Engeng Chen,Heng Chen,Zhangfa Song

DOI: https://doi.org/10.7150/thno.76869

IF: 11.6

2022-01-01

Theranostics

Abstract:[This corrects the article DOI: 10.7150/thno.52076.].

medicine, research & experimental
Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Qiuqiang Chen,Gang Jia,Xilin Zhang,Wenxue Ma

DOI: https://doi.org/10.3389/fimmu.2024.1376045

IF: 7.3

2024-01-31

Frontiers in Immunology

Abstract:[This corrects the article DOI: 10.3389/fimmu.2023.1332057.].

immunology
Correction to Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial

Hai Wang,Pranay Agarwal,Gang Zhao,Guang Ji,Christopher M Jewell,John P Fisher,Xiongbin Lu,Xiaoming He,Christopher M. Jewell,John P. Fisher

DOI: https://doi.org/10.1021/acscentsci.1c00530

IF: 18.2

2021-05-17

ACS Central Science

Abstract:[This corrects the article DOI: 10.1021/acscentsci.8b00050.].

chemistry, multidisciplinary
Correction: Tobramycin-mediated self-assembly of DNA nanostructures for targeted treatment of Pseudomonas aeruginosa -infected lung inflammation

Yuhang Xu,Qian Liu,Bin Wang,Quan Li,Yue Chen,Yao Yang,Zhihao Zhu,Daohui Gong,Chuan Zhang,Guansong Wang,Hang Qian

DOI: https://doi.org/10.1039/d4bm90084g

2024-10-30

Biomaterials Science

Abstract:Correction for 'Tobramycin-mediated self-assembly of DNA nanostructures for targeted treatment of Pseudomonas aeruginosa -infected lung inflammation' by Yuhang Xu et al. , Biomater. Sci. , 2024, 12 , 2331–2340, https://doi.org/10.1039/D3BM02121A.

materials science, biomaterials
Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer

Yuejie Zhu,Xiang Li,Qi Zhang,Xiantao Yang,Xudong Sun,Yi Pan,Xia Yuan,Yuan Ma,Bo Xu,Zhenjun Yang

DOI: https://doi.org/10.1039/d4md90013h

2024-01-01

RSC Medicinal Chemistry

Abstract:Correction for ‘Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer’ by Yuejie Zhu et al. , RSC Med. Chem. , 2024, https://doi.org/10.1039/d3md00752a.

biochemistry & molecular biology,chemistry, medicinal
Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance”

Akil A Kalathil,Subham Guin,Akash Ashokan,Uttara Basu,Bapurao Surnar,Katiana S Delma,Leonor M Lima,Oleksandr N Kryvenko,Shanta Dhar,Akil A. Kalathil,Katiana S. Delma,Leonor M. Lima,Oleksandr N. Kryvenko

DOI: https://doi.org/10.1021/acscentsci.3c00920

IF: 18.2

2023-08-08

ACS Central Science

Abstract:[This corrects the article DOI: 10.1021/acscentsci.3c00286.].

chemistry, multidisciplinary
Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Xiwei Ding,Yiyang Zhang,Tianlu Huang,Guifang Xu,Chunyan Peng,Gang Chen,Bo Kong,Helmut Friess,Shanshan Shen,Ying Lv,Lewis R Roberts,Lei Wang,Xiaoping Zou

2023-01-01

American journal of cancer research

Abstract:[This corrects the article on p. 546 in vol. 9, PMID: 30949409.].
Corrigendum: Docetaxel-loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Xing Feng,Xiaoling Xiong,Shenglin Ma

DOI: https://doi.org/10.3389/fphar.2022.964540

IF: 5.6

2022-01-01

Frontiers in Pharmacology

Abstract:[This corrects the article DOI: 10.3389/fphar.2022.832725.].
Correction: Ce6-Conjugated and Polydopamine-Coated Gold Nanostars with Enhanced Photoacoustic Imaging and Photothermal/photodynamic Therapy to Inhibit Lung Metastasis of Breast Cancer.

Ziwei Li,Fan Yang,Di Wu,Yanhong Liu,Yang Gao,Haichen Lian,Hongxin Zhang,Zhibin Yin,Aiguo Wu,Leyong Zeng

DOI: https://doi.org/10.1039/d4nr90194k

IF: 6.7

2024-01-01

Nanoscale

Abstract:Correction for 'Ce6-Conjugated and polydopamine-coated gold nanostars with enhanced photoacoustic imaging and photothermal/photodynamic therapy to inhibit lung metastasis of breast cancer' by Ziwei Li et al., Nanoscale, 2020, 12, 22173-22184, https://doi.org/10.1039/D0NR05386D.
Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]

Wang D,Xu X,Zhang K,Sun B,Wang L,Meng L,Liu Q,Zheng C,Yang B,Sun H

DOI: https://doi.org/10.2147/ijn.s349851

IF: 7.033

2021-01-01

International Journal of Nanomedicine

Abstract:Wang D, Xu X, Zhang K, et al. Int J Nanomedicine. 2018;13:187–198. The authors have advised due to an error at the time of figure assembly, Figure 5 on page 195 is incorrect. The correct Figure 5 is shown in Download Article. The authors apologize for this error and advise it does not affect the results of the paper. Read the original article

Correction To: Targeted Therapy for Cisplatin‐resistant Lung Cancer Via Aptamer‐guided Nano‐zinc Carriers Containing USP14 Sirna

Erratum: Targeting NF-κB/AP-2β Signaling to Enhance Antitumor Activity of Cisplatin by Melatonin in Hepatocellular Carcinoma Cells.

Correction: ShRNA-Targeted COMMD7 Suppresses Hepatocellular Carcinoma Growth.

Correction: The improved targeting of an aspirin prodrug albumin-based nanosystem for visualizing and inhibiting lung metastasis of breast cancer

Corrigendum: Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer

Correction To: MiRNA-195-5p Functions As a Tumor Suppressor and a Predictive of Poor Prognosis in Non-small Cell Lung Cancer by Directly Targeting CIAPIN1

Corrigendum: Dual-Targeting Nanoparticle-Mediated Gene Therapy Strategy for Hepatocellular Carcinoma by Delivering Small Interfering RNA

Preparation of AS1411 Aptamer Modified Mn-MoS2 QDs for Targeted MR Imaging and Fluorescence Labelling of Renal Cell Carcinoma [Corrigendum]

Corrigendum: Regulation of microrna-497-targeting AKT2 influences tumor growth and chemoresistance to cisplatin in lung cancer

Corrigendum: Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K–AKT Pathway and Activating the AMPK–ROS Pathway

Correction To: Therapeutic Efficacy, Pharmacokinetic Profiles, and Toxicological Activities of Humanized Antibody-Drug Conjugate Zt/g4-MMAE Targeting RON Receptor Tyrosine Kinase for Cancer Therapy

Co-delivery of 5-fluorouracil and miRNA-34a mimics by host-guest self-assembly nanocarriers for efficacious targeted therapy in colorectal cancer patient-derived tumor xenografts: Erratum

Corrigendum: Targeting HER3 to overcome RGFR TKI resistance in NSCLC

Correction to Overcoming Ovarian Cancer Drug Resistance with a Cold Responsive Nanomaterial

Correction: Tobramycin-mediated self-assembly of DNA nanostructures for targeted treatment of Pseudomonas aeruginosa -infected lung inflammation

Correction: Aptamer AS1411 interacts with the KRAS promoter/hnRNP A1 complex and shows increased potency against drug-resistant lung cancer

Correction to “New Pathway for Cisplatin Prodrug to Utilize Metabolic Substrate Preference to Overcome Cancer Intrinsic Resistance”

Erratum: Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma.

Corrigendum: Docetaxel-loaded Novel Nano-Platform for Synergistic Therapy of Non-Small Cell Lung Cancer

Correction: Ce6-Conjugated and Polydopamine-Coated Gold Nanostars with Enhanced Photoacoustic Imaging and Photothermal/photodynamic Therapy to Inhibit Lung Metastasis of Breast Cancer.

Codelivery of Doxorubicin and MDR1-siRNA by Mesoporous Silica Nanoparticles-Polymerpolyethylenimine to Improve Oral Squamous Carcinoma Treatment [Corrigendum]